Recurrent Gray Zone Lymphoma
3 clinical trials · Condition
◉ Watch Recurrent Gray Zone Lymphoma
| Record | Firm | Date |
|---|---|---|
| TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541) | Mayo Clinic | 2023-04-19 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553) | National Cancer Institute (NCI) | 2016-11-15 |
Track Recurrent Gray Zone Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.